Not All GLP-1 Receptor Agonists Are Alike: Real-World Evidence of Differential Endocrine and Dermatologic Safety - PubMed
5 hours ago
- #pharmacovigilance
- #endocrine safety
- #GLP-1 receptor agonists
- GLP-1 receptor agonists vary in safety profiles, with semaglutide linked to higher risks of alopecia and reproductive/endocrine issues like PCOS and menstrual abnormalities.
- Dulaglutide and tirzepatide showed lower or negative associations with reproductive adverse events, such as dysmenorrhea and amenorrhea.
- The study used FDA Adverse Event Reporting System data and disproportionality analyses to validate these agent-specific differences, emphasizing the need for personalized treatment and ongoing pharmacovigilance.